Partnerships, Licensing, Investments and M&A Deals and Trends for November 2017 in Pharmaceuticals
February 2018
77
About the Report
About the Report
Partnerships, Licensing, Investments and M&A Deals and Trends for November 2017 in Pharmaceuticals
Summary
GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for November 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.
The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in November 2017. The industry reported 375 deals worth USD26.8 billion in November 2017, compared to 444 deals worth USD32.3 billion in October 2017. The oncology therapeutics market remained at the top in deal activity in November 2017 with 110 deals. In second place, central nervous system therapeutics market reported 65 deals. Licensing agreements in pharmaceutical and healthcare industry registered an increase in upfront payments. The segment reported USD185.9m as upfront payments in November 2017, compared to USD57.4m in October 2017. The number of deals in North America a decreased to 219 in November 2017 from 298 in October 2017.
Scope
Analysis of the market trends for the pharmaceutical industry in the global arena.
Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
Analysis of partnership and licensing deals based on clinical stage of development of products.
Summary of the pharmaceutical deals globally in the six months.
Information on the top deals happened in the pharmaceutical industry.
Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
Enhance your decision making capability in a more rapid and time sensitive manner.
Find out the major deal performing segments for investments in your industry.
Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
Identify companies that are aggressively looking to raise capital in the market
Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
Identify growth segments and opportunities in each region within the industry.
Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Products
Table of Contents
Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceuticals & Healthcare, Global, Deal Summary
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, November 2017
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, November 2017
2.2.1 Anthem Raises USD5.5 Billion in Private Placement of Notes
2.2.2 Janssen Biotech Enters into Licensing Agreement with Zymeworks
2.2.3 Shanghai Pharma to Acquire China Business from Cardinal Health for USD1.2 Billion
2.2.4 Bayer and PeptiDream Enter into Partnership
2.2.5 Bayer Enters into Co-Development Agreement with Loxo Oncology
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, November 2017
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, November 2017
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, November 2017
3.1.1 Top M&A Deals in November 2017
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, June 2017-November 2017
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2017
3.2.1 Top Equity Offering Deals in November 2017
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, June 2017-November 2017
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2017
3.3.1 Top PE/VC Deals in November 20
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, November 2017
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, November 2017
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-November 2017
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-November 2017
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2017
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2017-November 2017
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (USD m), November 2017
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, November 2017
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), June 2017-November 2017
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, June 2017-November 2017
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (USD m), June 2017-November 2017
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), June 2017-November 2017
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2017
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2017
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), November 2017
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (USD m), June 2017-November 2017
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (USD m), June 2017-November 2017
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (USD m), June 2017-November 2017
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (USD m), June 2017-November 2017
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, November 2017
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, November 2017
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, November 2017
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2017
5.1.1 Oncology-Deals of the Month
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2017
5.2.1 Central Nervous System-Deals of the Month
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2017
5.3.1 Infectious Diseases-Deals of the Month
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 20
5.4.1 Cardiovascular-Deal of the Month
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2017
5.5.1 Immunology-Deals of the Month
5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, November 2017
5.6.1 Gastrointestinal-Deal of the Month
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, November 2017
5.7.1 Metabolic Disorders-Deal of the Month
6 Deal Summary by Geography
6.1 Pharmaceuticals & Healthcare, North America Deals, November 20
6.1.1 North America-Deals of the Month
6.2 Pharmaceuticals & Healthcare, Europe, Deals, November 2017
6.2.1 Europe-Deals of the Month
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, November 2017
6.3.1 Asia-Pacific-Deals of the Month
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2017
6.4.1 Rest of the World-Deals of the Month
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, June 2017-November 2017
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2017-November 2017
8 Further Information
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclosure information
8.5 Disclaimer
List of Figure
1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), November 2017
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), November 2017
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, June 2017-November 2017
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, June 2017-November 2017
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), November 2017
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), November 2017
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), June 2017-November 2017
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), June 2017-November 2017
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2017-November 2017
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2017-November 2017
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), June 2017-November 2017
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), June 2017-November 2017
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), June 2017-November 2017
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, June 2017-November 2017
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (USD m), June 2017-November 20
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (USD m), November 2017
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), June 2017-November 20
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (USD m), June 2017-November 20
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), June 2017-November 2017
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), June 2017-November 2017
List of Table
1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, November 2017
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), November 2017
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, November 2017
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), by Therapy Area, June 2017-November 2017
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, November 2017
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 20
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, November 20
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2017-November 2017
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), November 2017
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2017-November 2017
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), June 2017-November 2017
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (USD m), November 2017
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), June 2017-November 20
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2017-November 2017
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (USD m), June 2017-November 2017
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (USD m), June 2017-November 2017
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (USD m), November 2017
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2017-November 20
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), November 2017
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, November 2017
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, November 2017
Table 31:Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, November 2017
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 33:Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), June 2017-November 2017
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), June 2017-November 2017
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.